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Summary
 
Bacterial superantigens induce peripheral unresponsiveness in CD4
 
1
 
 T cell populations that ex-
press appropriate V
 
b
 
 chains. We have used V
 
b
 
3/V
 
a
 
11 T cell receptor transgenic (Tg) mice
and the V
 
b
 
3-specific superantigen staphylococcal enterotoxin A (SEA) to further investigate
the mechanisms that contribute to such unresponsiveness. As in other models, in vivo exposure
to SEA rendered the Tg CD4
 
1
 
 cells unresponsive to subsequent restimulation in vitro with an-
tigen or mitogens. However, when the SEA-treated CD4
 
1
 
 cells were completely purified
away from all other contaminating cells, they regained the ability to proliferate and secrete cy-
tokines. Moreover, enriched CD4
 
2
 
CD8
 
2
 
 cells from the SEA-treated mice suppressed the re-
sponses of fresh control CD4
 
1
 
 cells in mixed cultures indicating that the apparent “anergy” was
both transferable and reversible. Further analysis demonstrated that interferon 
 
g
 
, but not the
Fas receptor, played a critical role in the suppression.
 
U
 
nder optimum conditions, immune responses are tightly
regulated to prevent prolonged inflammation and in-
discriminate damage to healthy tissue. Multiple mechanisms
are known to contribute to the maintenance of immune
tolerance (1) including: deletion of self-reactive T cells
during thymic selection (2) and in the periphery (3–5) and
the induction of unresponsiveness or anergy among specific
B (6) and T cell subsets (7–10). However, the relative con-
tributions of these mechanisms to the in situ downregula-
tion of specific immune responses remain unclear in most
instances.
Many experimental models have been developed to
identify mechanisms that participate in the induction of tol-
erance, including injection of (11–13) and oral exposure to
(14) soluble proteins. Other models use natural superanti-
gens (SAg
 
1
 
; 15), such as those encoded by the mouse mam-
mary tumor virus genes (5). The fact that both bacteria and
viruses have independently evolved similar strategies to
subvert host immune responses suggests that SAg often play
an important role in host–pathogen interactions. It is there-
fore important to understand the mechanisms by which
SAg induce T cell anergy, both for the purpose of counter-
acting their effects and because similar strategies may partic-
ipate in other processes that the host uses to promote self
tolerance.
In contrast to some other polyclonal T cell activators,
SAg interact specifically with class II MHC molecules (16),
stimulating T cells through V
 
b
 
-restricted T cell–APC in-
teractions (17) in a way that closely mimics recognition of
peptide–MHC complexes. Thus, it is likely that SAg stim-
ulate T cells with similar avidities and via the same signal
transduction pathways as conventional antigens (18). In
vitro, bacterial SAg induce efficient IL-2 secretion and ef-
fector cell generation from purified CD4
 
1
 
 cells (19). How-
ever, in vivo, SAg induced proliferative responses are sur-
prisingly short lived with a short burst of T cell expansion
and massive cytokine production that can result in shock or
death (20, 21). The numbers of responding CD4
 
1
 
 cells
then fall rapidly as they undergo apoptosis (22, 23). Re-
maining cells, with appropriate V
 
b
 
 expression, become un-
responsive or anergic (20, 21). Some reports suggest that
anergy can be overcome by the introduction of IL-2 (24,
25) or removal of antigen (26), although this is not always
the case.
We have used the staphylococcal SAg, staphylococcal
enterotoxin A (SEA), injected into transgenic (Tg) AND
mice, to further investigate the mechanisms that downregu-
late CD4
 
1
 
 cells in vivo. AND mice express a V
 
a
 
11
 
1
 
V
 
b
 
3
 
1
 
1
 
Abbreviations used in this paper:
 
 AICD, activation-induced cell death; C
 
9
 
,
complement; DN, CD4
 
2
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2
 
 double negative; F/S, forward and side
light scatter; mRNA, messenger RNA; PCCF, peptide fragment of pi-
geon cytochrome; PI, propidium iodide; RT, reverse transcriptase; SAg,
superantigen; SEA, staphylococcal enterotoxin A; TdR, [H3]thymidine;
TdT, terminal deoxynucleotidyl transferase; Tg, transgenic.
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Staphylococcal Enterotoxin A Induces Transferable Anergy
 
TCR specific for a peptide fragment of pigeon cytochrome
C (PCCF) residues 88–104 and I-E
 
k
 
 class II MHC mole-
cules (27). More than 95% of peripheral CD4
 
1
 
 cells express
both chains of the Tg TCR and are naive in phenotype
(28, 29). In vitro, they generate active effector populations,
giving excellent proliferative responses and secreting high
titers of IL-2 in response to either PCCF (30, 31) or SEA
(Schuenke, K., G. Huston, and S. Swain, manuscript sub-
mitted). However, after SEA treatment, the Tg CD4
 
1
 
 cells
become anergic as defined by their inability to proliferate
or secrete cytokines upon restimulation. “Anergy” reaches
a maximum 5–7 d after injection, when a majority of the
Tg CD4
 
1
 
 cells shift from a naive phenotype to an activated
memory phenotype, and persist for several weeks (Schuenke,
K., G. Huston, and S. Swain, manuscript submitted).
By analyzing the response of a uniform population of Tg
CD4
 
1
 
 cells to in vivo SEA exposure, we have identified a
novel mechanism of T cell tolerance that depends on IFN-
 
g
 
,
but does not require Fas expression. We show that the an-
ergic CD4
 
1
 
 cells from the SEA-treated mice could be res-
cued from their unresponsive state either by high level pu-
rification such as FACS
 
Ò
 
 (Becton Dickinson, San Jose, CA)
sorting, or by the addition of neutralizing anti–IFN-
 
g
 
 Ab
to in vitro cultures. Moreover, enriched CD4
 
2
 
CD8
 
2
 
 cells
from the spleens of the SEA-treated mice were able to sup-
press control CD4
 
1
 
 cells in mixed cultures, suggesting that
the SAg-induced anergy was the result of an active process
of suppression, rather than an irreversible loss of autono-
mous T cell function.
 
Materials and Methods
 
Mice.
 
C57BL/6 (B6) 
 
3
 
 SJL founder AND Tg mice (27) were
backcrossed to B10.BR mice for six to eight generations. Mice
between 3–7 mo of age received a single injection (20 
 
m
 
g) of pu-
rified SEA (Toxin Technologies, Sarasota, FL) in HBSS by intra-
venous injection in the tail. Fas
 
2
 
 MRL-
 
lpr/lpr
 
 and syngeneic C3H
mice were obtained from Jackson Laboratories (Bar Harbor, ME).
 
Cell Lines.
 
Murine fibroblasts transfected with I-E
 
k
 
 class II
MHC molecules and intercellular adhesion meolcule 1 (DCEK
intercellular adhesion molecules), which also express high levels
of B7.1 (32), were used as APC.
 
T Cell Enrichment and Effector Cell Generation.
 
CD4
 
1
 
 cells were
enriched by Ab and complement (C
 
9
 
)-mediated depletion, using
anti–Thy 1.2 (HO.13.14), anti-heat stable antigen (J11D), anti–
class II MHC (D3.137, M5114, and CA4), and anti-CD8 (3.155)
Ab. Cell debris were removed with lympholyte separation gradi-
ents spun at 2.2 rpm for 20 min at room temperature. These
CD4
 
1
 
 cells, referred to as “enriched”, were cultured in RPMI
1,640 medium supplemented with penicillin (200 
 
m
 
g/ml), strep-
tomycin (200 
 
m
 
g/ml), 4 mM 
 
l
 
-glutamine, 10 mM Hepes, 50 
 
m
 
M
 
b
 
-mercaptoethanol, and 10% FCS at 3 
 
3
 
 10
 
5
 
/ml, with 10
 
5
 
 APC/ml,
5 
 
m
 
M PCCF, and 20 U/ml 
 
r
 
IL-2. Th1 and Th2 effector cells
were generated as previously reported (33) using 
 
r
 
IL-2 at 20 U/
ml, 
 
r
 
IL-12 (5 ng/ml), and anti–IL-4 (11B11) at 10 
 
m
 
g/ml for Th1
cells and 
 
r
 
IL-4 at 10 
 
m
 
g/ml with anti–IFN-
 
g
 
 (XMG1.2) at 10
 
m
 
g/ml for Th2 cells.
 
Positive Selection of CD4
 
1
 
 Cells.
 
“Pure” populations of CD4
 
1
 
cells were isolated by positive selection using magnetic columns
(
 
.
 
95% CD4
 
1
 
) or by sterile sorting (
 
.
 
99% CD4
 
1
 
) using a FACStar
Plus
 
Ò
 
 FACS
 
Ò
 
.
Before positive selection on Magnetic Cell Separation magnetic
columns (Miltenyi, Sunnyvale, CA), nonadherent cells were en-
riched on nylon wool columns for 1 h at 37
 
8
 
C. The nonadherent cells
were stained with Ab to CD4 coupled to magnetic beads, on ice for
30 min and passed over Magnetic Cell Separation columns to retain
the bead-coated CD4
 
1
 
 cells. The bound cells were eluted by re-
moving the magnet. The purity of the CD4
 
1
 
 cells was verified by
FACS
 
Ò
 
 analysis.
For sterile FACS
 
Ò
 
 sorting, splenic lymphocytes were enriched
using T cell enrichment columns (R&D Sys. Inc., Minneapolis,
MN). Eluted cells were stained with PE-conjugated anti-CD4
(PE-GK1.5) and further purified by sterile sorting on a FACSTAR
Plus
 
Ò
 
. The purified cells were incubated at 37
 
8
 
C for 1–2 h, before
stimulation with immobilized anti-CD3 Ab (2C11 at 10 
 
m
 
g/ml)
and 1 
 
m
 
g/ml soluble anti-CD28.
 
TUNEL Assay to Detect Apoptotic Cells.
 
Spleen cells were stained
with PE-conjugated anti-CD4, and then washed and fixed with
1% paraformaldehyde at 4
 
8
 
C for 15 min and permeabilized with
0.5 ml cold 70% ethanol at 4
 
8
 
C for 30 min. Fragmented DNA
was detected with exogenous terminal deoxynucleotidyl trans-
ferase (TdT; 34). End labeling was carried out in cacodylate
buffer (Boehringer Mannheim, Indianapolis, IN) with biotinylated
deoxy-uridine-triphosphate for 45 min at 37
 
8
 
C. The cells were
then stained with fluoresceinated strepavidin in 4
 
3
 
 SSC buffer,
5% nonfat milk, and 0.1% Triton X-100 for 30 min at room tem-
perature in the dark and analyzed by two-color FACS
 
Ò
 
 analysis.
 
Propidium Iodide Staining Used to Detect Dead Cells.
 
Splenocytes
were stained with FITC-conjugated anti-CD4 and washed with
PBS. 50 
 
m
 
l of fluorescent propidium iodide (PI) dye (at 100 
 
m
 
g/
ml) was added to each sample (10
 
6
 
 cells) immediately before two-
color FACS
 
Ò
 
 analysis (35). Gated cell populations were used to
identify dead and dying CD4
 
1
 
 cells as indicated in individual figures.
 
Detection of DNA Synthesis in CD4
 
1
 
 T Cells.
 
APC were treated
with 100 
 
m
 
g/ml mitomycin C for 30–40 min at 37
 
8
 
C and plated
at 10
 
5
 
/well with either 5 
 
m
 
M PCCF or 250 ng/ml SEA. Tripli-
cate cultures of CD4
 
1
 
 cells incubated at 37
 
8
 
C for 72 h, followed
by a 6-h pulse with TdR (28). TdR incorporation was deter-
mined by harvesting the lysed cells onto glass filters and counting
in a Wallace b counter.
Reverse Transcriptase for Detection of Cytokine Messenger RNA.
T cells were stimulated at 106/ml using plate-bound anti-CD3
Ab (2C11 at 10 mg/ml) and anti-CD28 (1 mg/ml). Total messen-
ger RNA (mRNA) was isolated from 1 or 2 3 106 cells as de-
scribed (36), quantitated by optical density, and visualized on de-
naturing formaldehyde agarose gels. Total cellular RNA was
analyzed for cytokine mRNA content by competitive, semiquan-
titative reverse transcriptase (RT)-PCR, using linearized PQRS
plasmid as competitor DNA as described (37). PQRS plasmid was
linearized with Not1 enzyme and extracted with phenol/chloro-
form. The cut plasmid was reprecipitated and quantitated by ab-
sorbance spectroscopy. Total cellular RNA (1 mg) was used in
each 20 ml reverse transcription reaction, carried out according to
the method of the manufacturer (GeneAmp RT-PCR kit; Per-
kin-Elmer Corp., Foster City, CA). The cDNA products of re-
verse transcription were amplified by 50 PCR amplification cy-
cles (37), with 2 ml of linearized competitor plasmid, diluted
through a half-log dilution series, in each sample.
Cytokine ELISA and Bioassays. An IL-2–dependent indicator
cell line (NK.3) was used to quantitate the IL-2 content of cul-
ture supernatants as previously described (38). NK.3 cells (104
cells/well) were cultured with anti–IL-4 (11B11) at 10 mg/ml,73 Cauley et al.
with rIL-2 for standard curves. After 24 h, the cells were pulsed
with TdR for 16 h and harvested on glass filters. The data are ex-
pressed as U/ml, where 1 U equals 50% of the maximum re-
sponse detected by the standard curve. One unit of IL-2 corre-
sponds to 14 pg of protein as determined by comparison to a
standard curve of murine rIL-2 in this assay. IL-4, IL-5, and IFN-g
concentrations were determined by sandwich ELISAs as de-
scribed (28, 38). 1 U of IFN-g equals the quantity of cytokine re-
quired to neutralize the viral destruction of L-929 cells by 50%, as
defined by Amgen Biologicals (Thousand Oaks, CA).
Results
SEA Treatment Induces Unresponsiveness of Tg CD41
Cells. To verify that SEA induces anergy in Tg CD41 cells,
AND mice were injected with 20 mg of SEA (intrave-
nously). 6–8 d later, splenic CD41 cells were enriched us-
ing Ab to CD8, class II MHC, and heat stable antigen to
deplete CD81 T and B cells. DNA synthesis and cytokine
production were used to assess the effect of the SAg treat-
ment. In a typical experiment, the enriched CD41 cells
from SEA-treated, but not control, mice failed to synthe-
size DNA over a wide range of cell numbers (Fig. 1 a) and
PCCF doses (Fig. 1 b). Even ionomycin (Ca21 ionophore)
and PMA, which together circumvent the need for TCR
signaling, elicited little response from the SEA-treated cells
as compared to the untreated control cells (Fig. 1 c).
Supernatants were also analyzed for cytokine content,
revealing substantial IL-2 production by the untreated con-
trol cells, in response to both SEA and PCCF. However,
after SEA treatment, only 1–200 U of IFN-g and small
quantities of IL-2 were detected in a representative experi-
ment (Fig. 1 d), further indicating that the CD41 cells were
broadly anergic after their in vivo exposure to the SAg.
Cells from SEA-treated Mice Suppress the Responses of Con-
trol CD41 Cells In Vitro. In non-Tg models, only a frac-
tion of the T cells respond to SAg and the response is het-
erogeneous even for a single Vb. Consequently, anergic
cells have rarely been isolated and the possibility that unre-
sponsiveness is maintained by a suppresser mechanism has
not been adequately addressed. To test for such a suppresser
mechanism in the AND mouse model, we added enriched
CD41 cells from the SEA-treated mice to control CD41
cells in mixed cultures (Fig. 2). Since DNA synthesis is a
precursor of cell division, but may not always correlate
with proliferation if cells undergo apoptosis, live cell recov-
eries were used to measure the extent of the CD41 cell re-
sponse.
Control CD41 cells were stimulated with mitomycin
C-treated APC, PCCF, and rIL-2, with increasing num-
bers of the SEA-treated cells (65% CD41). After 4 d, live
CD41 recovery was determined by trypan blue staining
and FACSÒ analysis. All live cell recoveries have been cor-
rected for CD41 content.
After enrichment, the control CD41 cells (Fig. 2 a, left)
contained small numbers of contaminating CD42CD82
(double negative; DN) Vb31 T cells (z8%). As expected,
these cells proliferated extensively in the presence of the
PCCF and APC, resulting in zfivefold expansions after
4  d. After enrichment, the SEA-treated cells were 65%
CD41 with 26% DN cells (Fig. 2 a, middle). The addition
of these SEA-treated cells (65% CD41) to control cultures
led to dramatically reduced CD41 recoveries, suggesting
Figure 1. Anergy of enriched CD41 T cells from SEA-treated trans-
genic mice. Tg CD41 cells were broadly unresponsive to antigenic restimula-
tion in vitro after in vivo exposure to SEA. [3H]thymidine incorporation
by CD41 T cells stimulated with (a) 5 mM PCCF and APCs, (b) increasing
concentrations of PCCF and APCs, and (c) other T cell mitogens. (d) Cy-
tokine production by CD41 T cells was also decreased by the in vivo SEA
treatment. Similar results were seen in at least three repeated experiments.
Figure 2. Cells from SEA-treated mice suppress control CD41 T cell
responses. (a) Purity of cells after purification with Ab and C9. (b) Anergic
cells from SEA-treated mice inhibited effector generation by normal
CD41 T cells in mixed wells. (c) Non-CD41 cells from SEA-treated mice
were sufficient for the suppression to be transferred between in vitro cul-
tures. Live CD41 T cell recovery on day 4 is shown.74 Staphylococcal Enterotoxin A Induces Transferable Anergy
that the anergy could be transferred. To determine if the
anergic CD41 cells were directly responsible for the trans-
ferred anergy, we treated an enriched population of SEA-
treated CD41 cells with anti-CD4 Ab. When the residual
cells (59% DN; Fig. 2 a, right) were mixed with control
cells (Fig. 2 c), the potency of the suppression was in-
creased, indicating that anergic CD41 cells were not re-
quired, but that non-CD41CD81 cells and/or factors they
produced were responsible for the suppression observed.
Extensive Purification of CD41 Cells from SEA-treated Mice
Restores In Vitro Proliferation and Cytokine Production. Exten-
sive purification procedures were used to determine whether
the anergic CD41 cells were intrinsically unresponsive or,
alternatively, were being influenced by other cells or factors
from the injected mice such as those responsible for the
trans suppression. Positive selection using magnetic bead
columns was used to generate pure populations of CD41
cells with ,1–5% contaminating non-CD41 cells from
both control and SEA treated mice (Fig. 3 a).
CD41 cells were also “enriched” with Ab and C9 treat-
ment (not shown) to verify that the SEA-mediated anergy
had occurred in the injected mice as expected. After 4 d in
culture with APC and PCCF (Fig. 3 b), very few live
CD41 cells were recovered from the SEA-treated samples,
confirming that anergy had been induced as expected. Af-
ter positive selection, the proliferative capacity of these cells
was significantly restored, resulting in 3.5–5-fold increases
in the size of the effector cell populations generated. Fur-
thermore, when anergic CD41 cells from the SEA-treated
mice were mixed 1:1 with the positively selected cells, live
CD41 cell recoveries were again reduced, demonstrating
that the rescued cells were still sensitive to the transferable
anergy.
We used sterile FACSÒ sorting to determine whether
cytokine production was restored by purification. Sorted
CD41 cells were stimulated and analyzed for the ability to
synthesize cytokine mRNA (Fig. 4). 24 h supernatants
were also analyzed for cytokine content (Fig. 5).
Sorted CD41 cells from both control and SEA-treated
mice synthesized detectable quantities of IL-2 and some
IFN-g mRNA in response to anti-CD3 and anti-CD28.
Very little IL-4 mRNA was detected (Fig. 4 A). The cy-
tokine mRNAs were quantitated by competitive RT-PCR,
using linearized PQRS plasmid as competitor DNA (37).
Live APC were not used for PCR experiments to avoid
RNA contamination. An example of this quantitative anal-
ysis is shown for IFN-g and IL-2 mRNAs analyzed 4 h af-
ter stimulation (Fig. 4 B). A broad range of competitor
DNA (pg/ml) concentrations were analyzed, and those
shown were chosen from the range that best reveals the
amount of cytokine mRNA detected in each sample. The
concentrations of IL-2 and IFN-g cDNA extrapolated
from several analyses are shown in Fig. 4 C. Unstimulated
CD41 cells from the SEA mice gave ,1 pg/ml of cDNA
for either cytokine. Upon stimulation, these mRNA levels
increased 30–100-fold, reaching a peak of 70 pg/ml for
IFN-g, and 100 pg/ml for IL-2. As expected (Fig. 4 C),
naive CD41 cells from untreated mice also synthesized IL-2
mRNA (70 pg/ml) and some IFN-g (20 pg/ml). The
RNA levels in the SEA-treated group, however, were
higher at an early time (4 h after stimulation) and fell off
more rapidly, indicating that the kinetics of the response
were more accelerated than in the control animals, but
were similar to those expected for effector cells (39). Since
effector cells (Th1 polarized), but not naive CD41 cells, are
very sensitive to Fas-mediated activation-induced cell death
(AICD; 40, 41), it is possible that rapid apoptosis of the
SEA-treated cells contributed to the decline in cytokine
mRNA detected.
As expected, the unsorted (enriched) CD41 cells from
SEA-treated mice produced very little IL-2 and only small
quantities of IFN-g. However, after sorting, the CD41
cells from protein SEA-treated and control mice produced
comparable levels of IFN-g and IL-2 protein (Fig. 5), but
neither IL-4 or IL-5 were detected. Thus, in the absence of
other contaminating cells, the CD41 cells from SEA-
treated mice were able to proliferate and secrete cytokines
upon restimulation, demonstrating that the anergy was not
an intrinsic property of the CD41 cells.
IFN-g Plays an Essential Role in the Suppression of CD41
T Cell Responses. Bacterial SAg induce massive cytokine
production in vivo, including large quantities of IFN-g (9,
42). Since small quantities of IFN-g were detected in the
anergic cultures from SEA-treated mice (Fig. 1 d), we
tested this cytokine for a role in the anergy using a neutral-
izing Ab to IFN-g.
Enriched populations of CD41 cells from SEA-treated
and control mice were stimulated in vitro with or without
anti–IFN-g (XMG1.2 at 10 mg/ml). After 48 and 96 h, the
Figure 3. (a) Purity of CD41 cells after enrichment with Ab and C9
(left) and positive selection on magnetic columns (right). (b) Number of
live CD41 cells recovered on day 4.75 Cauley et al.
recovery of live CD41 cells was determined (Fig. 6 a). In
this representative experiment, treatment with anti–IFN-g
increased the live CD41 recoveries in the SEA-treated
groups to levels that were comparable with the controls,
whereas in the absence of added Ab, no CD41 cell growth
occurred. Interestingly, anti–IFN-g had comparatively lit-
tle effect on the survival of control CD41 cells from un-
treated animals.
The 4-d cultures were also analyzed for cell death using a
combination of forward and side light scatter (F/S) and PI
staining (35). The control cells were 49% live by the crite-
ria of F/S (Fig. 6 b), with 54% of the CD41 cells staining
positively with PI (Fig. 6 c). Treatment with anti–IFN-g
(right) only modestly increased these numbers, giving 57%
live cell recovery by F/S, and slightly decreased the per-
centage of PI1 CD41 cells to 44%. In contrast to the con-
trols, the SEA-treated samples contained large numbers of
PI1 CD41 cells (83%) on day 4. Treatment with anti–IFN-g
increased the viability of these cells dramatically, giving
10-fold expansions from the plating numbers by day 4 (Fig.
6 a) and increased the live cell content of the culture from
16 to 62% by F/S (Fig. 6 b), whereas the percentage of PI1
CD41 cells decreased from 83 to only 15%.
To investigate whether IFN-g played a similar role in
the transferable suppression, we added anti–IFN-g to mixed
cultures of control CD41 cells with enriched CD42CD82
cells from SEA-treated mice (Fig. 7 a). As expected, the
cells from the SEA-treated mice suppressed the recovery of
fresh CD41 cells by 20-fold when mixed at a ratio of 1:1
(Fig. 2). The addition of anti–IFN-g to the mixed cultures
Figure 4. Extensively purified CD41 cells from SEA-treated mice can
synthesize cytokine mRNA. The SEA-mediated T cell anergy was re-
versed by FACSÒ sorting the CD41 cells. (A) PCR analysis of cytokine
mRNAs from SEA-treated and control CD41 T cells after high level pu-
rification by positive selection and restimulation with 2C11 and anti-
CD28 Ab. PCR products were electrophoresed on 1.5% agarose gels
stained with ethidium bromide. Competitor DNA is not shown. (B)
PCR products were quantitated using linearized PQRS plasmid as com-
petitor DNA. Upper band is the modified plasmid product and the lower
band represents cytokine mRNA product. Two bands indicates the
equivalence point of cDNA and plasmid DNA PCR products. RNA
from CD41 cells analyzed 4 h after restimulation is shown. PQRS plas-
mid concentration is shown in pg/ml. For IL-2 analysis, PQRS plasmid is
shown at 100 pg/ml for induced samples, and 0.1 pg/ml for uninduced
samples to show equivalence points before normalization to hypoxanthine
phosphoribosyl transferase. (C) Kinetic analysis of mRNA synthesized by
SEA-treated and control CD41 cells is shown. Data has been normalized
to hypoxanthine phosphoribosyl transferase.
Figure 5. Cytokine produc-
tion was restored by purification.
SEA-treated and control CD41
T cells were purified by sterile
FACSÒ sorting or enriched with
Ab and C9 and stimulated at 106
cells/ml with anti-CD3 and
-CD28. Supernatants were ana-
lyzed 24 h after restimulation us-
ing ELISA assays and prolifera-
tion assays with NK.3 cells.76 Staphylococcal Enterotoxin A Induces Transferable Anergy
restored the recovery of these cells to the levels seen when
no SEA-treated cells were added.
In Fig. 7 b, enriched cells from both control and SEA-
treated mice generated large populations of CD41 effector
cells in the presence of anti–IFN-g. However, significant
numbers of CD42CD82 cells also grew out (up to 30% in
some experiments not shown). Magnetic bead columns
were used to further purify the CD41 cells in this popula-
tion (.95% CD41 not shown) for cytokine analysis (Fig. 7 c).
The CD41 cells were then incubated overnight in the
presence of rIL-2, to allow the beads to fall off, and then
restimulated with APC and PCCF. Cytokine analysis re-
vealed high levels of IL-2 and IFN-g production by the
control cells, and high levels of IL-4 after SEA treatment,
with only low levels of IL-2 and IFN-g. Thus, the anti–
IFN-g treatment reversed the anergy and restored cytokine
production, resulting in a somewhat Th2-polarized cyto-
kine profile. Similar results were seen in a repeat experi-
ment.
CD41 Cells from SEA-treated Mice Are Suppressed by a Fas-
independent Mechanism. Since much peripheral T cell death
is mediated by Fas–FasL interactions (43), we investigated
the potential contribution of Fas-mediated suicide to the
anergy of the CD41 cells in our model. To do this we di-
rectly analyzed enriched CD41 cells from SEA-treated
AND mice for evidence of intracellular DNA damage (44)
by TUNEL staining. CD41 cells were isolated from the
spleens of untreated control (no SEA) and injected mice, 2
and 4 d after SEA treatment (two mice each). The enriched
cells were either restimulated in vitro with APC, PCCF,
and rIL-2 for 12 h, or analyzed immediately (ex vivo) for
DNA damage (Fig. 8). Gated populations of CD41 cells are
shown.
Less than 25% of the CD41 cells from untreated AND
mice were TdT positive when analyzed either immediately
ex vivo or 12 h after in vitro stimulation. However, 4 d af-
ter SEA injection, relatively large numbers of CD41 cells
had damaged DNA. Intermediate numbers of apoptotic
cells were found 2 d after SEA injection. Thus, large num-
bers of cells had undergone apoptosis as a result of the SEA
treatment.
To determine whether Fas–FasL interactions were medi-
ating cell death in the suppressed cultures, we compared
Fas-deficient CD41 cells from MRL-lpr/lpr mice (45) with
cells from syngeneic wild-type mice, as targets of the SEA-
mediated suppression in the transferable anergy model. En-
riched CD42CD82 cells from SEA-treated AND mice
were mixed with Fas-deficient CD41 cells from untreated
MRL-lpr/lpr mice (Fas2) or Fas-bearing (Fas1) cells from
wild-type controls (Fig. 9) and stimulated with APC, Con
A, and rIL-2. In both cases, the SEA-treated lymphocytes
Figure 6. Anti–IFN-g reverses SEA-induced anergy. Treatment with anti–IFN-g Ab increased CD41 T cell recovery and viability after SEA treat-
ment. (a) CD41 T cells from SEA-treated and control AND mice were cultured with neutralizing concentration of anti–IFN-g Ab (XMG1.2). Live cell
recovery on day 4 is shown. Cells recovered from above cultures were analyzed for live cell content. (b) Percentage of live cells as determined by F/S. (c)
Percentage of CD41 cells that stained positively with PI. Gated populations of CD41 cells are shown.
Figure 7. Anti–IFN-g reverses
the transferable suppression by
cells from SEA-treated mice. (a)
Mixed cultures of anergic and
control CD41 T cells were stim-
ulated with APCs and PCCF in
the presence and absence of the
neutralizing XMG1.2 Ab. Live
CD41 cell recovery on day 4 is
shown. (b) CD41 effector cells
generated in the presence of the XMG1.2 Ab develop the ability to se-
crete cytokines after antigenic restimulation. Effector cells were further
purified on magnetic bead columns and restimulated with PCCF and
APC. (c) 24-h supernatants were analyzed for cytokine content.77 Cauley et al.
suppressed the recovery of live CD41 cells (Fas1 and Fas2)
from untreated animals (Fig. 9, a and b, respectively). Both
cell recoveries were also substantially increased by the addi-
tion of anti–IFN-g Ab to the mixed wells. Thus, CD41
cells that lacked a functional Fas antigen could be sup-
pressed by the SEA-treated cells from AND mice by an
IFN-g–dependent mechanism, demonstrating that at least
some of the anergy was not mediated via Fas–FasL.
IFN-g has been suggested to downregulate cloned CD41
cells in vitro (46). To investigate the possibility that IFN-g
could sensitize normal CD41 cells to undergo apoptosis,
we generated polarized Th1 and Th2 effector cells from na-
ive CD41 Tg cells in vitro (33). After 4 d, the recovery of
these effector cells was z sevenfold higher than the initial
numbers plated, with only very small numbers of dead cells
(10–15% PI1). The effector cells were then washed, and
duplicate cultures were restimulated in the presence or ab-
sence of anti–IFN-g. When the cultures were analyzed for
dead cell content 24 h later by PI staining and FACSÒ anal-
ysis (Table 1), dead or dying CD41 cells were detected in
both populations, with the Th1 cells showing considerably
greater sensitivity to AICD (up to 60% cell death) than Th2
cells (40, 41). However, no significant effect of the neutral-
izing anti–IFN-g Ab was detected in either sample (Th1 or
Th2), as determined by the percentage of dead cells or
DNA synthesis.
We also investigated whether rIFN-g would suppress ef-
fector cell generation by naive CD41 cells. However, even
additions of .1,000 U/ml of exogenous rIFN-g, a high
dose compared with the small amounts (z200 U/ml) de-
tected in the suppressed cultures (Fig. 1), did not cause any
significant reduction in the size of the live cell population
generated over 4 d (Fig. 10). Thus, although IFN-g was
clearly required for the SEA-induced anergy, it was not
likely to be entirely responsible for the loss of CD41 cell
function.
Discussion
It has become clear that multiple mechanisms contribute
to the downregulation of T cell responses in vivo and are
likely recruited under distinct circumstances of antigen en-
counter. Since it is often difficult to identify rare antigen-
specific T cells in normal animals so that their fate can be
adequately monitored, many of the most productive studies
Figure 8. Apoptosis of CD41 T cells from SEA-treated Tg mice. TdT
staining revealed DNA fragmentation in the CD41 T cells from SEA-
treated mice. SEA-treated animals were analyzed 2 and 4 d after SEA in-
jection (two animals each), immediately ex vivo, and 12 h after antigenic
restimulation with APCs and PCCF. TdT staining of gated CD41 T cell
populations are shown.
Table 1. AICD of Normal Effectors Was Not Reversed
by Anti–IFN-g
Antibodies 3H incorporation PI1
cpm %
Th1 None 175,855 6 12,000 65
Th1 XMG1.2 160,860 6 9,717 58
Th2 None 186,166 6 8,074 26
Th2 XMG1.2 188,711 6 8,045 38
Figure 9. Fas-mediated death
is not required for transferable
anergy. Effector cell generation
by Fas-deficient CD41 T cells
from C3H.MRL-lpr/lpr mice (b)
and syngeneic controls (a) was
suppressed by splenocytes from
SEA-treated AND mice in
mixed cultures and could be re-
stored by anti–IFN-g Ab. The
number of live CD41 T cells re-
covered on day 4 is shown.78 Staphylococcal Enterotoxin A Induces Transferable Anergy
have used bacterial SAg to analyze large polyclonal popula-
tions of T cells. The experiments reported here document
the profound anergy induced in AND mice when SEA is
injected. Other studies have shown that the CD41 cells in
the Tg mice decrease somewhat in number as a result of
SEA injection and change to an activated/memory pheno-
type (Shub, F., and S.L. Swain, manuscript in preparation).
Enriched CD41 cells recovered from the SEA-treated mice
are anergic in that they fail to synthesize DNA or cytokines
in response to in vitro restimulation (Fig. 1). Surprisingly,
our studies show that this T cell unresponsiveness is not
CD41 cell–autonomous since the anergy could be trans-
ferred between in vitro cultures and extensive purification
restored the activity of the SEA-treated cells (Figs. 4 and 5).
Proteins with SAg properties are associated with growing
numbers of viruses and bacteria, and are thus relevant to
many natural immune responses. Studies show that T cell
anergy often develops after a transient period of hyperactiv-
ity (20, 21), and that the numbers of CD41 cells which sur-
vive in vivo SAg treatment can vary with the dose and
schedule of the injections used (47). In circumstances that
left large numbers of anergic CD41 cells, many surviving
cells acquired an activated phenotype (48), indicating that
they had responded to the SAg in vivo, yet failed to medi-
ate effector cell functions in vitro. However, under some
circumstances, T cell anergy can be reversed, and it has
been suggested that cytokines likely play a role (24, 25).
Most relevantly, studies by Ramsdell et al. (26) showed that
CD4 T cells recovered from mice that express endogenous
mouse mammary tumor viral SAg and regain function
when adoptively transferred to suitable recipients, demon-
strating the reversibility of anergy in that model.
In addition to bacterial SAg, several other methods of
tolerance induction lead to abortive expansions of CD41 T
cell populations in vivo (5, 13). In some instances, the sub-
sequent unresponsiveness was attributed to incomplete T
cell activation because of APC lacking necessary costimula-
tory molecules, such as resting B cells (11, 13, 49). The re-
sponse of CD41 cells to bacterial SAg, however, is para-
doxical in that SAg often elicit massive primary responses
from naive T cells before the onset of Vb-restricted unre-
sponsiveness (20, 21), and efficiently drive CD41 effector
cell generation in vitro (19), even though naive CD41 cells
are normally the most highly dependent upon costimula-
tion (30, 31). This suggests that a deficiency in initial anti-
gen exposure is an unlikely explanation for the anergy ob-
served in the SAg-treated animals. In this study, we show
that enriched CD42CD82 splenocytes from the SEA-
treated AND mice suppressed the responses of normal
CD41 in vitro (Fig. 3), suggesting that incomplete T cell
activation was not responsible for the apparent anergy ob-
served, but that other cells activated by the SEA treatment,
or factors produced by them, were responsible. The anergy
in the Tg model is therefore fundamentally distinct from
that induced in cell lines in vitro (50). In light of these ob-
servations, alternate pathways for the development of T cell
anergy to SAg need to be considered.
Some models have suggested that exhaustion (51) or de-
letion of specific responding cells (23) can play a role in the
induction of T cell unresponsiveness, and a number of
studies have focused on the role of Fas-mediated apoptosis
in the downregulation of CD41 cell responses in vivo (43,
52). The activated CD41 cells in SAg-treated mice are sim-
ilar to polarized Th1 cells (9), which are particularly sensi-
tive to AICD (40, 41). The Tg CD41 cells from the SEA-
treated AND mice exhibited some increased sensitivity to
apoptosis after SEA treatment. It is therefore possible that
Fas-mediated death contributed to the downregulation of
CD41 T cell responses in vivo. However, our studies show
that another mechanism which does not use the Fas antigen
accompanies T cell anergy in the AND model, since the
response of Fas-deficient CD41 T cells from C3H-lpr mice
(45) was suppressed by cells from SEA-treated mice (Fig. 9).
It is not clear which cells were responsible for the sup-
pression observed. Removal of CD41 and CD81 T and B
cells enhanced the suppressive capacity of the residual SEA-
treated cells (Fig. 2), implying that CD42CD82 cells were
involved. We have found that the residual cell population
contained an unusual population of CD42CD82CD31 TCR1
(DN) T cells (Shub, F., and S.L. Swain, unpublished data),
as well as a mixture of macrophages and other less well charac-
terized cell populations. It has recently been reported that
other TCR-ab Tg mice can contain unusual populations
of CD42CD82 T cells that are of g/d lineage, but that bear
the Tg TCR (53). We have not investigated the possibility
that the expanded populations of DN T cells found in
SEA-treated AND mice are of similar g/d lineage; how-
ever, our studies show that these cells can be stimulated in
vitro to give rise to functional effector cells that produce
high titers of IFN-g (Shub, F., and S.L. Swain, manuscript
in preparation).
Although we have shown that IFN-g is essential to the
SEA-mediated suppression in the AND model, rIFN-g did
not suppress effector cell generation by naive CD41 cells in
vitro (Fig. 10) and endogenous IFN-g was not required for
AICD of Th1 effector cells (Table 1). Furthermore, only
relatively small quantities of IFN-g were detected in the
suppressed cultures (100–200 U/ml), in comparison to the
large quantities produced by Th1 cells (.1,000 U/ml),
without significant effect on their ability to proliferate or
secrete cytokines. These results suggest that other cells or
factors from the SEA-treated mice were contributing to the
suppression, and raise the possibility that even states of pro-
found unresponsiveness may be the result of cell interac-
tions masquerading as tolerance.
Figure 10. rIFN-g does not
suppress CD41 cells from un-
treated AND mice. Naive CD41
T cells were stimulated with
APCs and PCCF in the presence
of increasing concentrations of
rIFN-g. Live CD41 T cell recov-
ery on day 4 is shown. Anti–
IFN-g also did not significantly al-
ter live cell recovery (not shown).79 Cauley et al.
Although the AND mice were profoundly unresponsive
after SEA treatment, it is interesting to note that the in-
jected animals experienced only transient discomfort as a
result of the SAg treatment, with insignificant increases in
mortality, even though almost all the T cells are capable of
responding to SEA (Cauley, L.S., G. Huston, and S.L.
Swain, unpublished data). It is possible that we have exag-
gerated the cytokine crisis experienced by the injected
mice by using TCR Tg mice, and may have recruited a
mechanism that would normally require much higher doses
of antigen in non-Tg animals. However, it is also possible
that the efficient downregulation of the CD41 T cell re-
sponses in these animals directly aids in their survival from
SAg-induced shock. If the DN cells in AND mice are of
g/d lineage, their response to SAg treatment may not be
entirely physiological. Our studies also suggest that the re-
sponse of these cells may be reminiscent of CD81 T cell re-
sponses to SAg treatment in non-Tg models (not shown).
In conclusion, we have shown a clear role for transfer-
able anergy in this model of SAg-induced unresponsiveness
and have identified a novel mechanism that may participate
in the downregulation of CD41 T cell responses. Our
studies show that the anergy produced in AND mice, and
detected in enriched populations of Tg CD41 cells recov-
ered from the injected animals, can be transferred between
in vitro cultures or reversed by high level purification of
the anergic CD41 T cells. In light of this observation, we
suggest that SAg-induced T cell anergy is not always au-
tonomous, but in some circumstances can result from sup-
pression mediated by non-CD41CD81 cells from the spleens
of the SAg-treated animals. Since the end result of the an-
ergy was a lack of cell growth and apoptosis upon restimu-
lation, we suggest that such a mechanism may contribute to
other forms of high-dose antigen-induced tolerance, and
that the Tg model we have used is suitable for defining
mechanisms involved in this suppression.
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